Baxter/$BAX
1D1W1MYTD1Y5YMAX
About Baxter
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
- Ticker
- $BAX
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 37,500
- Headquarters
- Deerfield, United States
- Website
- www.baxter.com
Baxter Metrics
BasicAdvanced
$14B
-
-$2.06
0.60
$0.20
0.15%
Price and volume
Market cap
$14B
Beta
0.6
52-week high
$30.00
52-week low
$15.73
Average daily volume
7.1M
Dividend rate
$0.20
Financial strength
Current ratio
1.946
Quick ratio
1.133
Long term debt to equity
142.79
Total debt to equity
156.449
Interest coverage (TTM)
3.90%
Profitability
EBITDA (TTM)
2,212
Gross margin (TTM)
35.88%
Net profit margin (TTM)
-9.27%
Operating margin (TTM)
8.12%
Effective tax rate (TTM)
-100.41%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
3.85%
Return on equity (TTM)
-14.37%
Valuation
Price to revenue (TTM)
1.215
Price to book
2.25
Price to tangible book (TTM)
-5.08
Price to free cash flow (TTM)
17.156
Free cash flow yield (TTM)
5.83%
Free cash flow per share (TTM)
1.577
Dividend yield (TTM)
0.74%
Forward dividend yield
0.15%
Growth
Revenue change (TTM)
5.36%
Earnings per share change (TTM)
570.93%
3-year revenue growth (CAGR)
-2.54%
10-year revenue growth (CAGR)
1.33%
3-year earnings per share growth (CAGR)
-28.51%
10-year earnings per share growth (CAGR)
-13.41%
3-year dividend per share growth (CAGR)
-44.34%
10-year dividend per share growth (CAGR)
-8.29%
What the Analysts think about Baxter
Analyst ratings (Buy, Hold, Sell) for Baxter stock.
Baxter Financial Performance
Revenues and expenses
Baxter Earnings Performance
Company profitability
Baxter News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.